Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742996 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Phase 3 study of Mantle Cell Lymphoma and B-cell Lymphoma, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06742996: Recruiting Phase 3 study of Mantle Cell Lymphoma and B-cell Lymphoma, sponsored by BeOne Medicines.
NCT06742996 is a Phase 3 study of Mantle Cell Lymphoma and B-cell Lymphoma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 300 participants, above the 101-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (197% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742996, a Phase 3 study of Mantle Cell Lymphoma and B-cell Lymphoma, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Primary Outcome
PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Sonrotoclax
- DRUG Placebo
Study Locations (20)
Florida
- Memorial Cancer Institute, Memorial Healthcare System - Pembroke Pines
- Cleveland Clinic Florida - Weston
Michigan
- University of Michigan - Ann Arbor
- The Cancer and Hematology Centers - Grand Rapids
Nebraska
- Nebraska Cancer Specialists St Francis Grand Island - Grand Island
- Nebraska Cancer Specialists - Omaha
North Carolina
- Atrium Health Levine Cancer Institute (Lci) - Charlotte
- Duke University - Durham
Alabama
- University of Alabama At Birmingham Hospital - Birmingham
Arizona
- Mayo Clinic Phoenix - Phoenix
Connecticut
- Yale University, Yale Cancer Center - New Haven
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2032-03-30 |
| Phase | Phase 3 |
What NCT06742996 shows while recruiting
NCT06742996 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (197% higher).
The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT06742996 names 20 study sites across 16 states, led by Florida, Michigan, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06742996 about?
NCT06742996 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)". The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
What is the current status of trial NCT06742996?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-03-05. Estimated completion is 2032-03-30.
What conditions does trial NCT06742996 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, B-cell Lymphoma.
What interventions are being tested in trial NCT06742996?
The interventions under investigation include: Zanubrutinib (DRUG), Sonrotoclax (DRUG), Placebo (DRUG).
Who is sponsoring clinical trial NCT06742996?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742996 being conducted?
This trial has 20 study locations across Alabama, Arizona, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06742996's enrollment target sits among peer trials
300 10th of 102 higher than 92 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
COMPLETED · Phase 3
-
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
COMPLETED · Phase 3
-
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI